{
  "turn_global_index": 444,
  "session_index": 39,
  "session_id": "577da76d_2",
  "turn_in_session": 7,
  "date": "2023/03/01 (Wed) 22:06",
  "role": "assistant",
  "content": "Advance purchase agreements (APAs) are a crucial tool for the EU to secure vaccine doses and ensure a steady supply. Here's how they work and what kind of guarantees they provide:\n\n**What are Advance Purchase Agreements (APAs)?**\n\nAPAs are contractual agreements between the EU (or individual countries) and vaccine manufacturers. In these agreements, the EU commits to purchasing a certain number of vaccine doses at a predetermined price, often with options to purchase additional doses in the future.\n\n**How do APAs work?**\n\n1. **Negotiation:** The EU negotiates with vaccine manufacturers to agree on the terms of the APA, including the number of doses, price, delivery schedule, and other conditions.\n2. **Commitment:** The EU commits to purchasing a certain number of doses, providing a guaranteed market for the manufacturer.\n3. **Manufacturer's commitment:** In return, the manufacturer commits to delivering the agreed-upon number of doses according to a specified schedule.\n4. **Options for additional doses:** APAs often include options for the EU to purchase additional doses at a later date, providing flexibility in case of increased demand or changes in the pandemic situation.\n\n**Guarantees and benefits:**\n\nAPAs provide several guarantees and benefits to ensure a steady vaccine supply:\n\n1. **Guaranteed supply:** APAs ensure that the EU has a guaranteed supply of vaccine doses, reducing the risk of shortages and supply chain disruptions.\n2. **Priority access:** By committing to purchase a large number of doses, the EU gains priority access to the manufacturer's production capacity, increasing the likelihood of timely delivery.\n3. **Price stability:** APAs can provide price stability, as the agreed-upon price is fixed for the duration of the agreement, protecting the EU from potential price increases.\n4. **Investment incentives:** APAs can incentivize manufacturers to invest in increasing their production capacity, as they have a guaranteed market for their products.\n5. **Risk sharing:** APAs can include risk-sharing provisions, where the EU and the manufacturer share the risks associated with vaccine development, production, and distribution.\n\n**Examples of EU APAs:**\n\nThe EU has signed APAs with several vaccine manufacturers, including:\n\n1. **AstraZeneca:** The EU has an APA with AstraZeneca for up to 400 million doses of their COVID-19 vaccine.\n2. **Pfizer-BioNTech:** The EU has an APA with Pfizer-BioNTech for up to 600 million doses of their Comirnaty vaccine.\n3. **Moderna:** The EU has an APA with Moderna for up to 160 million doses of their mRNA-1273 vaccine.\n\nThese APAs have helped the EU secure a significant number of vaccine doses and ensured a steady supply to support its vaccination efforts.\n\nI hope this helps you understand how APAs work and the guarantees they provide to ensure a steady vaccine supply!",
  "has_answer": false
}